UCB, Inc., UCB BioPharma SPRL, Research Corp. Technologies, Inc., and Harris FRC Corp. (collectively, “UCB”), the owner/ licensees of a patent covering lacosamide, an anti-epileptic drug marketed under the tradename Vimpat?, successfully resisted an appeal by generic manufacturers, as the U.S. Court of Appeals for the Federal Circuit found that the asserted claims were not invalid for obviousness-type double patenting, obviousness, or anticipation. Chief Judge Sharon Prost dissented, arguing that this was a case of double patenting (UCB, Inc. v. Accord Healthcare, Inc., May 23, 2018, Stoll, K.).
展开▼
